Home: Issue 7 2008 › Inhaling success
Inhaling success
22/01/2009 | Channel: Manufacturing
Presspart’s recent acquisition has given the company the opportunity to expand its product offerings into the area of plastic parts and assembled devices
Established in the 1970s, Presspart belongs to the Heitkamp & Thumann Group. With over 35 years’ experience in providing components to various industrial sectors, the company is now a leading supplier and partner to many of the world’s major pharmaceutical producers, such as GlaxoSmithKline, Boehringer Ingelheim and TevaIvax Pharmaceuticals. Presspart’s reputation for competence, quality and innovation places the company at the forefront of its game.
Joanna Riley, newly appointed marketing manager at Presspart, discusses the business: “From our plants in Lancashire (UK), Marsberg (Germany) and Tarragona (Spain) as well as sales offices in North Carolina (USA) and Shanghai (China), we specialise in high precision deep drawn metal and plastic injection moulded components for the pharmaceutical industry. We also provide specialist parts for other applications and industries, such as the pen refill market.”
Presspart, the leading manufacturer of pharmaceutical aerosol cans worldwide, has extensive experience in supplying cans, MDI valve components and new drug delivery device components. Joanna comments: “Our core business has traditionally been the manufacture of the metal canisters that are placed in the metered dose inhalers (MDI), through the deep drawn process – three quarters of all metered dose inhalers around the world incorporate components from Presspart. The recent acquisition of Nemo SA, a Spanish based provider of plastic components to the pharmaceutical and medical industry, will enable us to offer novel solutions to the pharmaceutical industry including assembled drug delivery devices ”
The company has recently developed novel can solutions, meeting the latest demands of the MDI industry as it moves from CFC to HFA propellants; Joanna expands: “For over fifty years CFC has been the propellant of choice for the metered dose inhaler, which is now being phased out in line with the Montreal Protocol and being replaced by HFA 134A and HFA 227 propellants. We have worked with our customers to create new solutions with HFA propellants, offering a range of cans to suit the application and formulation. We can also provide a coating on the inside of the can; depending on the drug formulation, it can react with the metal, so the coating acts as a barrier.
A non-stick coating can also reduce drug adhesion to the surface of the can. By working on this coating technology in house, we have given ourselves greater opportunities.”
')";>')";>
High-tech deep drawing, injection moulding, cleaning and coating processes allow the company to produce products that meet the high cleanliness and precision requirements of the pharmaceutical industry. “With a market such as pharmaceutical, you have to adhere to all the regulatory compliances. We’re constantly working with our customers to ensure our products are meeting the standards from a regulatory point of view. Pharmaceutical products are cleaned, coated and packed under clean room environment and we adhere to current Good Manufacturing Practices (cGMP) for the specific requirements of all industrial sectors,” Joanna comments. Presspart additionally complies with ISO 9001 and ISO 14001 standards; meeting the equirements of such standards, in facilities dedicated to pharmaceutical production, ensures that the best practices are adopted across the business.
Joanna continues: “The acquisition of Nemo in July 2008 is an excellent strategic fit within our established global pharmaceutical business. It has given Presspart the opportunity to expand its product offerings into the area of plastic parts and assembled devices.” With 50 years’ experience, Nemo, located close to Barcelona in the Tarragona region of Spain, is the largest global manufacturer of the metered dose inhaler (MDI) actuator.
The complementary product offerings of the two market-leading companies will expand Presspart’s input into the supply of precision components to the medical market. She elaborates: “With the acquisition, we’re now going to be looking at how we can use our deep drawing process in combination with our injection moulding plastic components facility. We will be addressing assembled drug delivery devices, rather than just components. In terms of the products we offer at the moment, they’re geared towards various forms of drug delivery including transdermal and pulmonary. Research is showing that the number of asthma and chronic obstructive pulmonary disease (COPD) cases are increasing and pulmonary drug delivery is a time-tested method suitable for the treatment of such diseases. It is additionally being looked at as a method of delivering relief from other therapeutic areas including migraine and schizophrenia.”
Looking towards the future, despite the economic situation, Presspart remains full of development opportunities: “We’re working with our customers in order to make our processes as efficient as possible, without jeopardising quality or safety, during these challenging market conditions. We’re constantly trying to improve our processes to ensure our customers are kept as competitive as we are,” Joanna concludes.
Presspart
www.presspart.com
Employees: 350
Industry: Pharmaceutical and medical
Joanna Riley, newly appointed marketing manager at Presspart, discusses the business: “From our plants in Lancashire (UK), Marsberg (Germany) and Tarragona (Spain) as well as sales offices in North Carolina (USA) and Shanghai (China), we specialise in high precision deep drawn metal and plastic injection moulded components for the pharmaceutical industry. We also provide specialist parts for other applications and industries, such as the pen refill market.”
Presspart, the leading manufacturer of pharmaceutical aerosol cans worldwide, has extensive experience in supplying cans, MDI valve components and new drug delivery device components. Joanna comments: “Our core business has traditionally been the manufacture of the metal canisters that are placed in the metered dose inhalers (MDI), through the deep drawn process – three quarters of all metered dose inhalers around the world incorporate components from Presspart. The recent acquisition of Nemo SA, a Spanish based provider of plastic components to the pharmaceutical and medical industry, will enable us to offer novel solutions to the pharmaceutical industry including assembled drug delivery devices ”
The company has recently developed novel can solutions, meeting the latest demands of the MDI industry as it moves from CFC to HFA propellants; Joanna expands: “For over fifty years CFC has been the propellant of choice for the metered dose inhaler, which is now being phased out in line with the Montreal Protocol and being replaced by HFA 134A and HFA 227 propellants. We have worked with our customers to create new solutions with HFA propellants, offering a range of cans to suit the application and formulation. We can also provide a coating on the inside of the can; depending on the drug formulation, it can react with the metal, so the coating acts as a barrier.
A non-stick coating can also reduce drug adhesion to the surface of the can. By working on this coating technology in house, we have given ourselves greater opportunities.”
')";>')";>
High-tech deep drawing, injection moulding, cleaning and coating processes allow the company to produce products that meet the high cleanliness and precision requirements of the pharmaceutical industry. “With a market such as pharmaceutical, you have to adhere to all the regulatory compliances. We’re constantly working with our customers to ensure our products are meeting the standards from a regulatory point of view. Pharmaceutical products are cleaned, coated and packed under clean room environment and we adhere to current Good Manufacturing Practices (cGMP) for the specific requirements of all industrial sectors,” Joanna comments. Presspart additionally complies with ISO 9001 and ISO 14001 standards; meeting the equirements of such standards, in facilities dedicated to pharmaceutical production, ensures that the best practices are adopted across the business.
Joanna continues: “The acquisition of Nemo in July 2008 is an excellent strategic fit within our established global pharmaceutical business. It has given Presspart the opportunity to expand its product offerings into the area of plastic parts and assembled devices.” With 50 years’ experience, Nemo, located close to Barcelona in the Tarragona region of Spain, is the largest global manufacturer of the metered dose inhaler (MDI) actuator.
The complementary product offerings of the two market-leading companies will expand Presspart’s input into the supply of precision components to the medical market. She elaborates: “With the acquisition, we’re now going to be looking at how we can use our deep drawing process in combination with our injection moulding plastic components facility. We will be addressing assembled drug delivery devices, rather than just components. In terms of the products we offer at the moment, they’re geared towards various forms of drug delivery including transdermal and pulmonary. Research is showing that the number of asthma and chronic obstructive pulmonary disease (COPD) cases are increasing and pulmonary drug delivery is a time-tested method suitable for the treatment of such diseases. It is additionally being looked at as a method of delivering relief from other therapeutic areas including migraine and schizophrenia.”
Looking towards the future, despite the economic situation, Presspart remains full of development opportunities: “We’re working with our customers in order to make our processes as efficient as possible, without jeopardising quality or safety, during these challenging market conditions. We’re constantly trying to improve our processes to ensure our customers are kept as competitive as we are,” Joanna concludes.
Presspart
www.presspart.com
Employees: 350
Industry: Pharmaceutical and medical